1
|
Camacho RC, You S, D'Aquino KE, Li W, Wang Y, Gunnet J, Littrell J, Qi JS, Kang L, Jian W, MacDonald M, Tat T, Steiner D, Zhang YM, Lanter J, Patch R, Zhang R, Li J, Edavettal S, Edwards W, Dinh T, Wang LY, Connor J, Hunter M, Chi E, Swanson RV, Leonard JN, Case MA. Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity. MAbs 2021; 12:1794687. [PMID: 32744157 PMCID: PMC7531507 DOI: 10.1080/19420862.2020.1794687] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The long circulating half-life and inherently bivalent architecture of IgGs provide an ideal vehicle for presenting otherwise short-lived G-protein-coupled receptor agonists in a format that enables avidity-driven enhancement of potency. Here, we describe the site-specific conjugation of a dual agonist peptide (an oxyntomodulin variant engineered for potency and in vivo stability) to the complementarity-determining regions (CDRs) of an immunologically silent IgG4. A cysteine-containing heavy chain CDR3 variant was identified that provided clean conjugation to a bromoacetylated peptide without interference from any of the endogenous mAb cysteine residues. The resulting mAb-peptide homodimer has high potency at both target receptors (glucagon receptor, GCGR, and glucagon-like peptide 1 receptor, GLP-1R) driven by an increase in receptor avidity provided by the spatially defined presentation of the peptides. Interestingly, the avidity effects are different at the two target receptors. A single dose of the long-acting peptide conjugate robustly inhibited food intake and decreased body weight in insulin resistant diet-induced obese mice, in addition to ameliorating glucose intolerance. Inhibition of food intake and decrease in body weight was also seen in overweight cynomolgus monkeys. The weight loss resulting from dosing with the bivalently conjugated dual agonist was significantly greater than for the monomeric analog, clearly demonstrating translation of the measured in vitro avidity to in vivo pharmacology.
Collapse
Affiliation(s)
| | | | | | - Wenyu Li
- Janssen R&D , Spring House, PA, USA
| | | | | | | | | | - Lijuan Kang
- Pharmacokinetics, Dynamics, and Metabolism, Janssen R&D , Spring House, PA, USA
| | - Wenying Jian
- Pharmacokinetics, Dynamics, and Metabolism, Janssen R&D , Spring House, PA, USA
| | - Mary MacDonald
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Timothy Tat
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Derek Steiner
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | | | | | | | | | - Jiali Li
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | | | - Wilson Edwards
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Thai Dinh
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Li Ying Wang
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Judy Connor
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Michael Hunter
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Ellen Chi
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | - Ronald V Swanson
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| | | | - Martin A Case
- Janssen Biotherapeutics, Janssen R&D , San Diego, La Jolla, CA, USA
| |
Collapse
|
2
|
Winters MP, Sui Z, Wall M, Wang Y, Gunnet J, Leonard J, Hua H, Yan W, Suckow A, Bell A, Clapper W, Jenkinson C, Haug P, Koudriakova T, Huebert N, Murray WV. Erratum to "Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes" Bioorg. Med. Chem. Lett. 28 (2018) [841-846]. Bioorg Med Chem Lett 2018; 28:1676-1678. [PMID: 29605534 DOI: 10.1016/j.bmcl.2018.03.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Michael P Winters
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA.
| | - Zhihua Sui
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Mark Wall
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Yuanping Wang
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Joseph Gunnet
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - James Leonard
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Hong Hua
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Wen Yan
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Arthur Suckow
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Austin Bell
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Wilmelenne Clapper
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Celia Jenkinson
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Peter Haug
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Tatiana Koudriakova
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Norman Huebert
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - William V Murray
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| |
Collapse
|
3
|
Winters MP, Sui Z, Wall M, Wang Y, Gunnet J, Leonard J, Hua H, Yan W, Suckow A, Bell A, Clapper W, Jenkinson C, Haug P, Koudriakova T, Huebert N, Murray WV. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes. Bioorg Med Chem Lett 2018; 28:841-846. [PMID: 29456108 DOI: 10.1016/j.bmcl.2018.02.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 02/05/2018] [Accepted: 02/07/2018] [Indexed: 02/02/2023]
Abstract
The discovery of a novel series of N-arylpyrroles as agonists of GPR120 (FFAR4) is discussed. One lead compound is a potent GPR120 agonist, has good selectivity for related receptor GPR40 (FFAR1), has acceptable PK properties, and is active in 2 models of Type 2 Diabetes in mice.
Collapse
Affiliation(s)
- Michael P Winters
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA.
| | - Zhihua Sui
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Mark Wall
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Yuanping Wang
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Joseph Gunnet
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - James Leonard
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Hong Hua
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Wen Yan
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Arthur Suckow
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Austin Bell
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Wilmelenne Clapper
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Celia Jenkinson
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Peter Haug
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Tatiana Koudriakova
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Norman Huebert
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - William V Murray
- Cardiovascular and Metabolism Research, Janssen Research and Development LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| |
Collapse
|
4
|
Zhang X, Cai C, Sui Z, Macielag M, Wang Y, Yan W, Suckow A, Hua H, Bell A, Haug P, Clapper W, Jenkinson C, Gunnet J, Leonard J, Murray WV. Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes. ACS Med Chem Lett 2017; 8:947-952. [PMID: 28947942 DOI: 10.1021/acsmedchemlett.7b00233] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Accepted: 07/27/2017] [Indexed: 01/01/2023] Open
Abstract
We have discovered a novel series of isothiazole-based phenylpropanoic acids as GPR120 agonists. Extensive structure-activity relationship studies led to the discovery of a potent GPR120 agonist 4x, which displayed good EC50 values in both calcium and β-arrestin assays. It also presented good pharmaceutical properties and a favorable PK profile. Moreover, it demonstrated in vivo antidiabetic activity in C57BL/6 DIO mice. Studies in WT and knockout DIO mice showed that it improved glucose handling during an OGTT via GPR120. Overall, 4x possessed promising antidiabetic effect and good safety profile to be a development candidate.
Collapse
Affiliation(s)
- Xuqing Zhang
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Chaozhong Cai
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Zhihua Sui
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Mark Macielag
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Yuanping Wang
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Wen Yan
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Arthur Suckow
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Hong Hua
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Austin Bell
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Peter Haug
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Wilma Clapper
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Celia Jenkinson
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - Joseph Gunnet
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - James Leonard
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| | - William V. Murray
- Cardiovascular and Metabolic Research, Janssen Research & Development, LLC, Welsh & McKean Roads, Box 776, Spring House, Pennsylvania 19477, United States
| |
Collapse
|
5
|
Jain N, Allan G, Linton O, Tannenbaum P, Chen X, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Murray W, Sui Z. Synthesis and SAR study of novel pseudo-steroids as potent and selective progesterone receptor antagonists. Bioorg Med Chem Lett 2009; 19:3977-80. [DOI: 10.1016/j.bmcl.2009.01.095] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2008] [Revised: 01/26/2009] [Accepted: 01/27/2009] [Indexed: 10/21/2022]
|
6
|
Kang FA, Guan J, Jain N, Allan G, Linton O, Tannenbaum P, Chen X, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z. Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists. Bioorg Med Chem Lett 2007; 17:2531-4. [PMID: 17317167 DOI: 10.1016/j.bmcl.2007.02.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2007] [Revised: 02/05/2007] [Accepted: 02/06/2007] [Indexed: 10/23/2022]
Abstract
Efficient parallel synthesis of novel 7-oxa-steroids 4 has been achieved from the key intermediate 3 via a one-pot four-step sequence. oxa-Steroids 4 with various ortho-, meta-, and para-monosubstituents on the phenyl ring, as well as disubstituted phenyl and heterocycles, were evaluated for progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist activities. SAR study demonstrated that the para-fluorinated substituents on the phenyl ring not only increased the potency for PR in a T47D cell functional assay, but also improved the selectivity over GR in an A549 cell functional assay. The para-fluorophenyl oxa-steroid 4l and the para-trifluoromethylphenyl oxa-steroid 4p were found to be remarkably more potent and more selective PR antagonists than mifepristone, with subnanomolar potency and about 140-fold selectivity over GR. Molecular modeling of the oxa-steroid bound to PR provided meaningful insight for the SAR study. oxa-Steroids 4a and 4b were found to be more efficacious than mifepristone in vivo in a rat uterine complement C3 assay via the oral route, although they were less than or equally potent to mifepristone in the T47D assay.
Collapse
Affiliation(s)
- Fu-An Kang
- Johnson and Johnson Pharmaceutical Research and Development, LLC, 665 Stockton Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Jiang W, Fiordeliso JJ, Allan G, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z. Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. Bioorg Med Chem Lett 2007; 17:1471-4. [PMID: 17258455 DOI: 10.1016/j.bmcl.2006.10.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2006] [Revised: 09/29/2006] [Accepted: 10/03/2006] [Indexed: 10/24/2022]
Abstract
Mifepristone is a non-selective antagonist of 3-oxosteroid receptors with both abortifacient and anti-diabetic activities. For glucocorticoid receptor (GR) program, we sought an unexplored, synthetically accessible phosphorus-containing steroidal mimetic of mifepristone, suitable for parallel synthesis of analogues. One compound 4a, with high oral bioavailability (59%) in rat, exhibited functional antagonism of GR in oral glucose tolerance test (OGTT). Thus this series of compounds might be potentially useful for the treatment of type II diabetes.
Collapse
Affiliation(s)
- Weiqin Jiang
- Johnson & Johnson Pharmaceutical Research & Development L.L.C., Drug Discovery, 1000 Route 202, Raritan, NJ 08869, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kang FA, Allan G, Guan J, Jain N, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Chen X, Demarest K, Lundeen S, Sui Z. Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists. Bioorg Med Chem Lett 2007; 17:907-10. [PMID: 17169557 DOI: 10.1016/j.bmcl.2006.11.062] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2006] [Revised: 11/14/2006] [Accepted: 11/20/2006] [Indexed: 11/29/2022]
Abstract
A novel series of oxa-steroids 6 derived from (8S, 13S, 14R)-7-oxa-estra-4,9-diene-3,17-dione 1 have been synthesized and identified as potent and selective progesterone receptor antagonists. These novel oxa-steroids showed similar potency to mifepristone. Preliminary SAR study resulted in the most potent 17-phenylethynyl oxa-steroid 6i wih an IC(50) of 1.4nM. In contrast to the equipotent mifepristone toward the progesterone receptor (PR) and glucocorticoid receptor (GR), compound 6i had over 200-fold selectivity for PR over GR.
Collapse
Affiliation(s)
- Fu-An Kang
- Johnson and Johnson Pharmaceutical Research and Development, LLC, 665 Stockton Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Jiang W, Allan G, Chen X, Fiordeliso JJ, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z. Novel phosphorus-containing 17beta-side chain mifepristone analogues as progesterone receptor antagonists. Steroids 2006; 71:949-54. [PMID: 16934845 DOI: 10.1016/j.steroids.2006.07.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2006] [Revised: 06/19/2006] [Accepted: 07/04/2006] [Indexed: 10/24/2022]
Abstract
A novel series of steroidal compounds were designed and synthesized with various phosphorus-containing groups on the 17beta-side chain as progesterone receptor antagonists. The structure-activity relationships of these compounds are discussed. Selected compounds were tested in an rat progesterone-sensitive assay. Some of these compounds are more potent than mifepristone, with a better selectivity profile in differentiating progesterone receptor from glucocorticoid receptor.
Collapse
Affiliation(s)
- Weiqin Jiang
- Johnson & Johnson Pharmaceutical Research & Development L.L.C., Drug Discovery, Raritan, NJ 08869, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Jiang W, Allan G, Fiordeliso JJ, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z. New progesterone receptor antagonists: phosphorus-containing 11beta-aryl-substituted steroids. Bioorg Med Chem 2006; 14:6726-32. [PMID: 16806946 DOI: 10.1016/j.bmc.2006.05.066] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2006] [Revised: 05/22/2006] [Accepted: 05/30/2006] [Indexed: 11/18/2022]
Abstract
A new series of phosphorus-containing 11beta-aryl-substituted steroids have been synthesized in an eight-step sequence involving a palladium-catalyzed coupling reaction to introduce a phosphorus group onto the aromatic ring. The compounds were evaluated for progesterone receptor (PR) antagonist activity in a T47D cell-based assay and for glucocorticoid receptor (GR) antagonist activity in an A549 cell-based assay. The structure-activity relationships of these compounds are discussed. Selected compounds were tested in vivo in a rat complement C3 assay.
Collapse
Affiliation(s)
- Weiqin Jiang
- Johnson & Johnson Pharmaceutical Research & Development L.L.C., Drug Discovery, 1000 Route 202, Raritan, NJ 08869, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Matthews J, Hlasta D, Andrade-Gordon P, Demarest K, Ericson E, Gunnet J, Hageman W, Look R, Moore J, Maryanoff B. Pyrazinobenzodiazepines as Potent Nonpeptide Vasopressin Receptor Antagonists. LETT DRUG DES DISCOV 2005. [DOI: 10.2174/1570180053765183] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
12
|
Xiang MA, Chen RH, Demarest KT, Gunnet J, Look R, Hageman W, Murray WV, Combs DW, Patel M. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists. Bioorg Med Chem Lett 2005; 14:2987-9. [PMID: 15125974 DOI: 10.1016/j.bmcl.2004.02.103] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2004] [Accepted: 02/18/2004] [Indexed: 10/26/2022]
Abstract
A novel series of spirobenzazepines was synthesized and evaluated for V1a and V2 receptor antagonist activity. Compounds 8b, 8i, and 8k have shown selective V1a receptor antagonist activity. Compounds 8p and 8q were shown to be dual V1a/V2 receptor antagonists.
Collapse
Affiliation(s)
- Min Amy Xiang
- Endocrine Therapeutics and Metabolic Disorders, Johnson and Johnson Pharmaceutical Research and Development, L.L.C. 1000 Route 202, Bldg: PCC; Room: PC110, Raritan, NJ 08869-0602, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Urbanski MJ, Chen RH, Demarest KT, Gunnet J, Look R, Ericson E, Murray WV, Rybczynski PJ, Zhang X. 2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists. Bioorg Med Chem Lett 2004; 13:4031-4. [PMID: 14592501 DOI: 10.1016/j.bmcl.2003.08.051] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A number of 2,5-disubstituted benzothiazepines were synthesized and screened for their ability to inhibit arginine vasopressin binding to the human V(2) and V(1a) receptor subtypes. The more active compounds were subsequently analyzed for their antagonist activity in in vitro functional assays. The SAR showed a preference for an acidic unit appended from the benzothiazepine scaffold. This substitution pattern afforded the most potent and selective analogues in the series. The carboxymethyl analogue 4, showed a 140-fold greater selectivity for the V(2) over the V(1a) receptor in the binding assay. In the cell-based functional assays this analogue was a potent and selective antagonist of the V(2) receptor. The in vitro SAR of the series and a description of the in vivo studies around compound 4 is described.
Collapse
Affiliation(s)
- Maud J Urbanski
- Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, Raritan, NJ 08869-0602, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Xiang MA, Chen RH, Demarest KT, Gunnet J, Look R, Hageman W, Murray WV, Combs DW, Rybczynski PJ, Patel M. Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists. Bioorg Med Chem Lett 2004; 14:3143-6. [PMID: 15149662 DOI: 10.1016/j.bmcl.2004.04.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2004] [Accepted: 04/07/2004] [Indexed: 10/26/2022]
Abstract
A series of substituted spirobenzazepines was prepared and evaluated as V(1a) and V(2) dual vasopressin receptor antagonists. Compounds 7p and 7q have been shown to be not only potent inhibitors of vasopressin receptors, but also have exhibited an excellent overall pharmaceutical suitability profile.
Collapse
Affiliation(s)
- Min Amy Xiang
- Endocrine Therapeutics and Metabolic Disorders, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Bldg: PCC, Room: PC110, Raritan, NJ 08869, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Caldwell GW, Easlick SM, Gunnet J, Masucci JA, Demarest K. In vitro permeability of eight beta-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J Mass Spectrom 1998; 33:607-614. [PMID: 9692244 DOI: 10.1002/(sici)1096-9888(199807)33:7<607::aid-jms672>3.0.co;2-o] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
It is demonstrated that the apparent permeability (P(app)) coefficients of beta-adrenoceptor antagonist drugs can easily be determined for Caco-2 cell culture intestinal models utilizing liquid chromatography/mass spectrometry (LC/MS). The LC/MS method with electrospray ionization in the single ion monitoring mode showed an increased sensitivity of 1000-fold compared with LC/UV detection and enhanced selectivity with respect to both LC/UV and radioactivity assays. The P(app) coefficients of beta-adrenoceptor antagonists determined by LC/MS have the same ranking order as those determined by LC/UV and radioactivity assays. However, the P(app) coefficients determined in this study showed significant discrepancies from those determined in other laboratories. There are several experimental factors that directly affect the absolute value of the P(app) coefficients, including pH gradients, additional diffusion barriers (i.e. unstirred water layer and type of filter support), analyte concentration, detection method and possibly cell culture variations. These parameters should be controlled when generating Caco-2 P(app) coefficients for different compounds.
Collapse
Affiliation(s)
- G W Caldwell
- R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
| | | | | | | | | |
Collapse
|
16
|
Rivier J, Theobald P, Porter J, Perrin M, Gunnet J, Hahn DW, Rivier C. Gonadotropin releasing hormone antagonists: novel structures incorporating N omega-cyano modified guanidine moieties. Biochem Biophys Res Commun 1991; 176:406-12. [PMID: 1850267 DOI: 10.1016/0006-291x(91)90939-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A series of GnRH antagonists with substitutions at positions 1, 2, 3, 5 and 6 that included the recently reported homoArg-N omega-cyano-N omega'-alkyl- or Lysine-N epsilon-5'-(3-amino-1H-1,2,4-triazole) [Lys(atz)] amino acid derivatives was synthesized, characterized and tested for antiovulatory and anaphylactoid activities and binding affinity. Overall, these analogs were found to be considerably more soluble at neutral pH than their homologs Nal-Glu or Antide. The decapeptides with these substitutions in positions 5 and/or 6 retained high in vivo potency while those with similar substitutions at positions 1, 2 and 3 were significantly less potent than Nal-Glu or Antide. Of the 16 new analogs reported here, Azaline (Ac-DNal1, DCpa2, DPal3, Lys5(atz),DLys6(atz), ILys8,DA1a10]-GnRH) showed the most promising physico-chemical and biological properties [Lys(atz) = N epsilon-5'-(3-amino-1H-1,2,4-triazole) lysine]. Azaline is readily soluble in dilute buffers at pH 7.0, completely inhibits ovulation at 2.0 to 3.0 micrograms per rat, is equipotent to GnRH in releasing histamine in the rat and has a weaker anaphylactoid response in the rat than other analogs such as Nal-Glu or even Antide.
Collapse
Affiliation(s)
- J Rivier
- Salk Institute for Biological Studies, La Jolla, California 92037
| | | | | | | | | | | | | |
Collapse
|